Europe Migraine Treatment Market - Industry Trends and Forecast to 2027

Report ID: | Publihed: 04-Jan-2020 | No of Pages: 140


USD 3995
USD 5795

Publish Date:


Total pages:


Europe migraine treatment market is projected to register a CAGR of 12.2% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027
Market Segmentation:
Europe Migraine Treatment Market, By Types of Migraine (Episodic, Migraine with Aura, Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/Prophylactic Treatment, Non-Pharmacological Therapies and Devices), Route of Administration (Oral, Parenteral, Nasal Sprays and Others), Product Type (Prescription and Over the Counter), Type (Branded and Generic), End User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Switzerland, Rest of Europe) Industry Trends and Forecast to 2027
Some of the major factors contributing to the growth of the Europe migraine treatment market are:

• Rising awareness programs
• Availability of large number of generic drugs
Market Players:
The key market players for global migraine treatment market are listed below:
• Eli Lilly and Company
• AstraZeneca
• Amgen Inc
• Allergan
• Pfizer Inc
• GlaxoSmithKline plc
• Bausch Health Companies Inc
• Abbott
• Dr. Reddy’s Laboratories Ltd
• Lundbeck
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd (A Subsidiary of Otsuka Holdings Co., Ltd)
• Catalent, Inc
• Bayer AG
• Sun Pharmaceutical Industries Ltd

Report Subsumes the following

Competitors Analysis Go To Market Strategies
Regional Coverage with precise Market Numbers Global Impact post Covid-19
Market Penetration Strategies Granular breakdown By Type and By Application.